今日，华芢生物科技（青岛）股份有限公司（以下简称“华芢生物”）成功登陆港交所，股票代码为2396.HK，联系保荐人为华泰国际、中信证券。成立于2012年的华芢生物，是港股首家以血小板衍生生长因子（PDGF）药物为核心的创新生物制药上市公司。目前，全球PDGF药物市场仅有Regranex一款药物获得美国FDA批准上市，国内尚无PDGF药物商业化，该赛道尚属蓝海。华芢生物所在的蓝海赛道也获得了资本的...
Source Link今日，华芢生物科技（青岛）股份有限公司（以下简称“华芢生物”）成功登陆港交所，股票代码为2396.HK，联系保荐人为华泰国际、中信证券。成立于2012年的华芢生物，是港股首家以血小板衍生生长因子（PDGF）药物为核心的创新生物制药上市公司。目前，全球PDGF药物市场仅有Regranex一款药物获得美国FDA批准上市，国内尚无PDGF药物商业化，该赛道尚属蓝海。华芢生物所在的蓝海赛道也获得了资本的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.